Licensing Partnerships Longevity Biotech's Hybridtide long-acting oral peptide platform positions it for licensing or co-development deals with pharma companies seeking novel peptide delivery. Target interest areas include MS and other chronic diseases highlighted by past funding. Proactive outreach to mid- to late-stage biotech firms and traditional pharma with peptide modality programs could unlock strategic partnerships.

CDMO Collaboration With a small team, they likely benefit from outsourced development and manufacturing. Propose CDMO partnerships to provide peptide synthesis, formulation development for oral delivery, and GMP manufacturing support to advance candidates toward the clinic. Emphasize risk-sharing co-development models to reduce early-stage program risk for potential partners.

Therapeutic Focus The prior National MS Society grant indicates susceptibility to MS-related programs; expand outreach to neurodegenerative and inflammatory indications where long-acting peptides offer competitive advantages. Frame Hybridtide as a platform to improve patient adherence and outcomes, which can resonate with sponsors seeking differentiated oral peptide therapies.

Grant Collaborations Past grant funding suggests readiness for public-private collaborations and joint development agreements. Explore partnerships to combine platform capabilities, preclinical data generation, and translational studies with pharma, biotech, or academic consortia, potentially supported by government or nonprofit funding.

Regional Partnerships Located in Philadelphia with a lean team, Longevity Biotech can benefit from regional partnerships with East Coast academic centers, CROs, and biotech incubators to accelerate milestones. Target BD channels include local universities, MS societies, and regional pharma affiliates to build a pipeline of collaboration opportunities.